Golden
Arzeda

Arzeda

Arzeda is a biotechnology and software company designing custom microorganisms for industrial applications through computational enzyme design, protein optimization, and metabolic engineering.

All edits

Edits 6 days ago
Golden AI
Golden AI edited 6 days ago
Edits made to:
Infobox (+1 properties)

Infobox

Funding rounds
Edits on 20 Feb 2019
Melanie Manipula
Melanie Manipula approved a suggestion from Golden's AI on 20 Feb 2019 6:36 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 12:23 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 17 Nov 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Nov 2018 1:59 am
Edits made to:
Infobox (-4 properties)
Article (+20/-20 characters)

Article

Arzeda is a biotechnology company designing custom organisms using knowledge of synthetic biology and computational biology for the production of specialty and bulk chemical products. Arzeda uses its own proprietary softwareproprietary software for computational enzyme design, protein optimization, and metabolic engineering to create organisms that are intended to produce chemicals on an industrial scale. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini. 

Edits on 15 Nov 2018
Melanie Manipula"Approved suggestion from source: https://arzeda.com/"
Melanie Manipula approved a suggestion from Golden's AI on 15 Nov 2018 12:09 am
Edits made to:
Infobox (+1 properties)
Edits on 10 Nov 2018
Tianchang He
Tianchang He approved a suggestion from Golden's AI on 10 Nov 2018 12:24 am
Edits made to:
Article (+14/-14 characters)

Article

On November 11, 2015 Arzeda announced a partnership with Stratos Genomics, a biotechnology company developing DNA sequencingDNA sequencing technologies. Stratos Genomcs hopes to leverage the software, enzyme engineering, and metabolic bioengineering technologies of Arzeda to advance its own "Sequence by Expansion" (SBX) technology. SBX is an enzyme enabled rapid prototyping system for the construction of single molecule DNA sequences. Arzeda will aid Stratos Genomics in making enzymes that improve upon enzymes being used in SBX technology. 

Jude Gomila"Approved suggestion from source: https://arzeda.com/"
Jude Gomila approved a suggestion from Golden's AI on 9 Nov 2018 11:38 pm
Edits made to:
Infobox (+1 properties)
Edits on 31 Aug 2018
Maxx Chatsko
Maxx Chatsko edited on 31 Aug 2018 1:10 pm
Edits made to:
Article (+597/-714 characters)

Article

Arzeda is a biotechnology company designing custom organisms using knowledge of synthetic biology, cellular agricultural, and computational biology technologies for the production of specialty and bulk chemical products. Arzeda uses theirits own proprietary software technologies for computational enzyme design, protein optimization, and metabolic engineering to create organisms capablethat ofare chemicalintended productionto produce chemicals on an industrial scale. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini. 

...

Arzeda uses computer simulations to design up to 10^37 possible enzymes capable of performing a certain biochemical function. TheirIts computational system then tests the potential enzymes under multiple conditions through simulations in an attempt to see which enzyme design is optimal for specific cases. The best candidates are then selected to be made in the lab and tested in real-world settings. 

...

Azeda uses theirits in-house software for protein optimization called Archytas. Archytas is capable of identifying high energy areas within protein structures and come up with designs that improve enzyme function and/or add or subtract biochemical properties of an enzyme. 

...

Arzeda combines theirits enzyme design and protein optimization techniques with their bioengineering tools to create novel metabolic pathways. TheirIts metabolic engineering system is compromised ofcomprises three steps: identify existing enzymes with the desired properties, re-engineer enzymes to perform desired function, and design new enzymes capable of novel biological functions. By combining these three processes Arzeda is able to design completely new metabolic pathways capable of producing desired products. 

...

On December 8, 2009 Arzeda received a $149,000 grant from the National Science Foundation on December 8, 2009 for a 6-monthsix-month contract to try and create an enzyme capable of producing butadiene. 

...

On December 12, 2013 Arzeda recieved an undisclosed amount of grant funding from the Advanced Research Projects Agency - Energy division(ARPA-E) in conjunction with the University of Washington for the development of a bioreactor system with the ability to convert methane to methanol. 

...

On July 20, 2017 Arzeda completed theirits Series-A funding round raising $12,000,000 from OS Fund (lead investor), Bioeconomy Capital, Washington Research Foundation, Sustainable Conversion Ventures, and Conversion Ventures. 

...

On July 14, 2009 Arzeda announced theirits first partnership agreement. TheyIt will be partnering up with Dupont's business Pioneer Hi-Bred to increase agricultural productivity through the creation of more efficient crop strains such as corn, soybeans, rice, cotton, and canola. DuPont will have ownership and rights to anything produced during the collaboration. 

...

Arzeda and INVISTA announced they will be partnering up on February 6, 2013. The two companies agreed to collaborate on the development of technologies which can help enable the creation of new bio-derived processes. INVISTA provides their knowledge in the fields of biotechnology, chemicals, and catalysis for integration into Arzeda's software platforms in hopes of accelerating technological development for both companies. 

On February 6, 2013 Arzeda announced a partnership with INVISTA. The two companies agreed to collaborate on the development of technologies which can help enable the creation of new bio-derived processes. INVISTA will provide knowledge in the fields of biotechnology, chemicals, and catalysis for integration into Arzeda's software platforms in hopes of accelerating technological development for both companies. 

...

On November 11, 2015 Arzeda announced theira partnership with Stratos Genomics, a biotechnology company developing DNA sequencing technologies, on November 11, 2015. Stratos Genomcs hopes to leverage the software, enzyme engineering, and metabolic bioengineering technologies of Arzeda to advance theirits own "Sequence by Expansion" (SBX) technology. SBX is an enzyme enabled rapid prototyping system for the construction of single molecule DNA sequences. Arzeda will aid Stratos Genomics in making enzymes that improve upon enzymes being used in SBX technology. 

...

On February 16, 2016 Mitsubishi Rayon announced theyit will be working with Arzeda on February 16, 2016 to improve the process of producing a specific chemical building block they useused in several applications. Arzeda is using theirits Archytas protein design software and Mitsubishi Rayon will be offering their expertise in process development and industrialization. The general manager of Mitsubishi Rayon's research and development administration department had the following to say about the Arzeda partnership, "Through our own experience and expertise, as well as with innovative technology like Arzeda’s, Mitsubishi Rayon can meet the growing global demand for a range of products in a sustainable manner."

...

On March 21, 2016 Arzeda and Zymergen announced a multi-year deal to work together on developing new strains of organisms capable of manufacturing valuable molecules and materials. Arzeda is offering Zymergen access to theirits metabolic bioengineering, protein optimization, and enzyme design software and technologies; and Zymergen is offering Arzeda access to theirits strain construction technologies. Alexandre Zanghellini, the CEO of Arzeda, said the following about partnering up withthe Zymergenpartnership, "Uniting with Zymergen's innovative strain design platform has the potential to help make our designs a reality. Zymergen's scientists are constantly pushing the envelope in synthetic biology, and we are thrilled to be working with their team." 

Edits on 13 Aug 2018
Dawson Sewell
Dawson Sewell edited on 13 Aug 2018 3:25 pm
Edits made to:
Description (+193/-348 characters)
Topic thumbnail

Arzeda

Arzeda is a biotechnology company designing custom organisms using synthetic biology, cellular agricultural, and computational biology techniques for the production of specialty and bulk chemical products. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini.

Arzeda is a biotechnology and software company designing custom microorganisms for industrial applications through computational enzyme design, protein optimization, and metabolic engineering.

Dawson Sewell
Dawson Sewell edited on 13 Aug 2018 3:22 pm
Edits made to:
Article (+34/-10 characters)

Article

Arzeda is a biotechnology company designing custom organisms using knowledge of synthetic biology, cellular agricultural, and computational biology techniquestechnologies for the production of specialty and bulk chemical products. Arzeda uses their own proprietary software technologies for computational enzyme design, protein optimization, and metabolic engineering to create organisms capable of chemical production on an industrial scale. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini. 

Edits on 21 Jul 2018
Jude Gomila
Jude Gomila edited on 21 Jul 2018 3:19 pm
Edits made to:
Article (+6/-6 characters)

Article

Azeda uses their in-house software for protein optimization called Archytas. Archytas is capable of identifying high energyenergy areas within protein structures and come up with designs that improve enzyme function and/or add or subtract biochemical properties of an enzyme. 

Edits on 19 Jul 2018
Jude Gomila
Jude Gomila edited on 19 Jul 2018 6:20 pm
Edits made to:
Article (+8/-8 characters)

Article

On March 21, 2016 Arzeda and ZymergenZymergen announced a multi-year deal to work together on developing new strains of organisms capable of manufacturing valuable molecules and materials. Arzeda is offering Zymergen access to their metabolic bioengineering, protein optimization, and enzyme design software and technologies; and Zymergen is offering Arzeda access to their strain construction technologies. Alexandre Zanghellini, the CEO of Arzeda, said the following about partnering up with Zymergen "Uniting with Zymergen's innovative strain design platform has the potential to help make our designs a reality. Zymergen's scientists are constantly pushing the envelope in synthetic biology, and we are thrilled to be working with their team." 

Dawson Sewell"Completed partnership and timeline sections. Plus added a couple more articles to further reading and a few crosslinks. "
Dawson Sewell edited on 19 Jul 2018 3:24 pm
Edits made to:
Timeline (+5 events) (+2421 characters)
Article (+2999/-616 characters)
Further reading (+12 cells) (+593 characters)
Related Topics (+1 topics)

Article

Arzeda is a biotechnology company designing custom organisms using synthetic biologysynthetic biology, cellular agriculturalcellular agricultural, and computational biologycomputational biology techniques for the production of specialty and bulk chemical products. Arzeda uses their own proprietary technologies for computational enzyme design, protein optimization, and metabolic engineering to create organisms capable of chemical production on an industrial scale. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini. 

...

Grant from the National Science Foundation

Arzeda received a $149,000 grant from the National Science Foundation on December 8, 2009 for a 6-month contract to try and create an enzyme capable of producing butadiene. 

Grant from Advanced Research Projects Agency - Energy

On December 12, 2013 Arzeda recieved an undisclosed amount of grant funding from the Advanced Research Projects Agency - Energy division in conjunction with the University of Washington for the development of a bioreactor system with the ability to convert methane to methanol. 

...

Stratos Genomics

Arzeda announced their partnership with Stratos Genomics, a biotechnology company developing DNA sequencing technologies, on November 11, 2015. Stratos Genomcs hopes to leverage the software, enzyme engineering, and metabolic bioengineering technologies of Arzeda to advance their own "Sequence by Expansion" (SBX) technology. SBX is an enzyme enabled rapid prototyping system for the construction of single molecule DNA sequences. Arzeda will aid Stratos Genomics in making enzymes that improve upon enzymes being used in SBX technology. 

DuPont — Pioneer Hi-Bred

On July 14, 2009 Arzeda announced their first partnership agreement. They will be partnering up with Dupont's business Pioneer Hi-Bred to increase agricultural productivity through the creation of more efficient crop strains such as corn, soybeans, rice, cotton, and canola. DuPont will have ownership and rights to anything produced during the collaboration. 

...

Stratos Genomics

Arzeda announced their partnership with Stratos Genomics, a biotechnology company developing DNA sequencing technologies, on November 11, 2015. Stratos Genomcs hopes to leverage the software, enzyme engineering, and metabolic bioengineering technologies of Arzeda to advance their own "Sequence by Expansion" (SBX) technology. SBX is an enzyme enabled rapid prototyping system for the construction of single molecule DNA sequences. Arzeda will aid Stratos Genomics in making enzymes that improve upon enzymes being used in SBX technology. 

Mitsubishi Rayon

Mitsubishi Rayon announced they will be working with Arzeda on February 16, 2016 to improve the process of producing a specific chemical building block they use in several applications. Arzeda is using their Archytas protein design software and Mitsubishi Rayon will be offering their expertise in process development and industrialization. The general manager of Mitsubishi Rayon's research and development administration department had the following to say about the Arzeda partnership “Through our own experience and expertise, as well as with innovative technology like Arzeda’s, Mitsubishi Rayon can meet the growing global demand for a range of products in a sustainable manner."

Zymergen

On March 21, 2016 Arzeda and Zymergen announced a multi-year deal to work together on developing new strains of organisms capable of manufacturing valuable molecules and materials. Arzeda is offering Zymergen access to their metabolic bioengineering, protein optimization, and enzyme design software and technologies; and Zymergen is offering Arzeda access to their strain construction technologies. Alexandre Zanghellini, the CEO of Arzeda, said the following about partnering up with Zymergen "Uniting with Zymergen's innovative strain design platform has the potential to help make our designs a reality. Zymergen's scientists are constantly pushing the envelope in synthetic biology, and we are thrilled to be working with their team." 

Further reading

Author
Title
Link
Type

Arzeda

Arzeda Strengthens Board of Directors with Addition of Biotechnology Veteran William Baum

News article

Nanalyze

6 Protein Engineering Startups Designing Biology - Nanalyze

Web article

Related Topics

Timeline

Partnership: DuPont — Pioneer Hi-Bred

On July 14, 2009 Arzeda announced their first partnership agreement. They will be partnering up with Dupont's business Pioneer Hi-Bred to increase agricultural productivity through the creation of more efficient crop strains such as corn, soybeans, rice, cotton, and canola. DuPont will have ownership and rights to anything produced during the collaboration. 

Grant from the National Science Foundation

Arzeda received a $149,000 grant from the National Science Foundation on December 8, 2009 for a 6-month contract to try and create an enzyme capable of producing butadiene. 

Grant from Advanced Research Projects Agency - Energy

On December 12, 2013 Arzeda recieved an undisclosed amount of grant funding from the Advanced Research Projects Agency - Energy division in conjunction with the University of Washington for the development of a bioreactor system with the ability to convert methane to methanol. 

Partnership: Mitsubishi Rayon

Mitsubishi Rayon announced they will be working with Arzeda on February 16, 2016 to improve the process of producing a specific chemical building block they use in several applications. Arzeda is using their Archytas protein design software and Mitsubishi Rayon will be offering their expertise in process development and industrialization. The general manager of Mitsubishi Rayon's research and development administration department had the following to say about the Arzeda partnership “Through our own experience and expertise, as well as with innovative technology like Arzeda’s, Mitsubishi Rayon can meet the growing global demand for a range of products in a sustainable manner."

Partnership: Zymergen

On March 21, 2016 Arzeda and Zymergen announced a multi-year deal to work together on developing new strains of organisms capable of manufacturing valuable molecules and materials. Arzeda is offering Zymergen access to their metabolic bioengineering, protein optimization, and enzyme design software and technologies; and Zymergen is offering Arzeda access to their strain construction technologies. Alexandre Zanghellini, the CEO of Arzeda, said the following about partnering up with Zymergen "Uniting with Zymergen's innovative strain design platform has the potential to help make our designs a reality. Zymergen's scientists are constantly pushing the envelope in synthetic biology, and we are thrilled to be working with their team." 

Dawson Sewell
Dawson Sewell edited on 19 Jul 2018 1:52 pm
Edits made to:
Related Topics (+1 topics)

Related Topics

Dawson Sewell
Dawson Sewell edited on 19 Jul 2018 1:51 pm
Edits made to:
Related Topics (+1 topics)

Related Topics

Edits on 18 Jul 2018
Jude Gomila
Jude Gomila edited on 18 Jul 2018 1:08 am
Edits made to:
Article (+18/-18 characters)

Article

Arzeda combines their enzyme design and protein optimization techniques with their bioengineering tools to create novel metabolic pathwaysmetabolic pathways. Their metabolic engineering system is compromised of three steps: identify existing enzymes with the desired properties, re-engineer enzymes to perform desired function, and design new enzymes capable of novel biological functions. By combining these three processes Arzeda is able to design completely new metabolic pathways capable of producing desired products. 

Infobox

Jude Gomila
Jude Gomila edited on 18 Jul 2018 1:08 am
Edits made to:
Article (+18/-18 characters)

Article

On July 20, 2017 Arzeda completed their Series-A funding round raising $12,000,000 from OS Fund (lead investor), Bioeconomy CapitalBioeconomy Capital, Washington Research Foundation, Sustainable Conversion Ventures, and Conversion Ventures. 

Infobox

Jude Gomila
Jude Gomila edited on 18 Jul 2018 1:08 am
Edits made to:
Article (+7/-7 characters)

Article

On July 20, 2017 Arzeda completed their Series-A funding round raising $12,000,000 from OS FundOS Fund (lead investor), Bioeconomy Capital, Washington Research Foundation, Sustainable Conversion Ventures, and Conversion Ventures. 

Infobox

Dawson Sewell"Still need to update partners section with the following companies: Mitsubishi Rayon Zymergen DuPont Pioneer National Science Foundation ARPA-E. Will be doing this tomorrow. "
Dawson Sewell edited on 17 Jul 2018 11:52 pm
Edits made to:
Timeline (+4 events) (+977 characters)
Description (+50 characters)
Article (+2861 characters)
Further reading (+12 cells) (+579 characters)
Related Topics (+1 topics)
Topic thumbnail

Arzeda

Arzeda is a biotechnology company designing custom organisms using synthetic biology, cellular agricultural, and computational biology techniques for the production of specialty and bulk chemical products. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini.

Article

Arzeda is a biotechnology company designing custom organisms using synthetic biology, cellular agricultural, and computational biology techniques for the production of specialty and bulk chemical products. Arzeda uses their own proprietary technologies for computational enzyme design, protein optimization, and metabolic engineering to create organisms capable of chemical production on an industrial scale. The company is located in Seattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini. 

Services

Enzyme design

Arzeda uses computer simulations to design up to 10^37 possible enzymes capable of performing a certain biochemical function. Their computational system then tests the potential enzymes under multiple conditions through simulations in an attempt to see which enzyme design is optimal for specific cases. The best candidates are then selected to be made in the lab and tested in real-world settings. 

Protein optimization

Azeda uses their in-house software for protein optimization called Archytas. Archytas is capable of identifying high energy areas within protein structures and come up with designs that improve enzyme function and/or add or subtract biochemical properties of an enzyme. 

Metabolic bioengineering

Arzeda combines their enzyme design and protein optimization techniques with their bioengineering tools to create novel metabolic pathways. Their metabolic engineering system is compromised of three steps: identify existing enzymes with the desired properties, re-engineer enzymes to perform desired function, and design new enzymes capable of novel biological functions. By combining these three processes Arzeda is able to design completely new metabolic pathways capable of producing desired products. 

Funding

Seed

On February 27, 2009 Arzeda received and undisclosed amount of seed funding from the Washington Research Foundation. 

Series-A

On July 20, 2017 Arzeda completed their Series-A funding round raising $12,000,000 from OS Fund (lead investor), Bioeconomy Capital, Washington Research Foundation, Sustainable Conversion Ventures, and Conversion Ventures. 

Partners

Stratos Genomics

Arzeda announced their partnership with Stratos Genomics, a biotechnology company developing DNA sequencing technologies, on November 11, 2015. Stratos Genomcs hopes to leverage the software, enzyme engineering, and metabolic bioengineering technologies of Arzeda to advance their own "Sequence by Expansion" (SBX) technology. SBX is an enzyme enabled rapid prototyping system for the construction of single molecule DNA sequences. Arzeda will aid Stratos Genomics in making enzymes that improve upon enzymes being used in SBX technology. 

INVISTA

Arzeda and INVISTA announced they will be partnering up on February 6, 2013. The two companies agreed to collaborate on the development of technologies which can help enable the creation of new bio-derived processes. INVISTA provides their knowledge in the fields of biotechnology, chemicals, and catalysis for integration into Arzeda's software platforms in hopes of accelerating technological development for both companies. 



Further reading

Author
Title
Link
Type

Daniela Quaglia

Synbio at the BioWorld Congress in Montréal | PLOS Synthetic Biology Community

Web article

Jim Lane

This is an algorithm, that is alive: The rise of Arzeda and Digital Biology : Biofuels Digest

Web article

Monica Nickelsburg

Startup Spotlight: This biotech company uses fermentation to produce custom compounds

Web article

Infobox

Related Topics

Timeline

Founding of Arzeda

Arzeda was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini. 

Completion of Seed funding round

On February 27, 2009 Arzeda received and undisclosed amount of seed funding from the Washington Research Foundation. 

Partnership: INVISTA

Arzeda and INVISTA announced they will be partnering up on February 6, 2013. The two companies agreed to collaborate on the development of technologies which can help enable the creation of new bio-derived processes. INVISTA provides their knowledge in the fields of biotechnology, chemicals, and catalysis for integration into Arzeda's software platforms in hopes of accelerating technological development for both companies. 

Completion of Series-A funding round

On July 20, 2017 Arzeda completed their Series-A funding round raising $12,000,000 from OS Fund (lead investor), Bioeconomy Capital, Washington Research Foundation, Sustainable Conversion Ventures, and Conversion Ventures. 

Jude Gomila
Jude Gomila edited on 17 Jul 2018 10:01 pm
Edits made to:
Article (+7/-7 characters)

Article

Arzeda is a biotechnology company designing custom organisms using synthetic biology techniques for the production of specialty and bulk chemical products. The company is located in SeattleSeattle, Washington and was founded in 2008 by Eric Althoff, David Baker, Daniela Grabs, and Alexandre Zanghellini.

Infobox